94.75

0.73% -0.70

Medtronic Plc (MDT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Medtronic Plc stock is traded at $94.75, with a volume of 28.49M. It is down -0.73% in the last 24 hours and up +2.32% over the past month. One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Previous Close:

$95.45

Open:

$95.83

24h Volume:

28.49M

Relative Volume:

0.59

Market Cap:

$121.20B

Revenue:

$36.36B

Net Income/Loss:

$4.84B

P/E Ratio:

25.43

EPS:

3.7261

Net Cash Flow:

$5.43B

1W Performance:

+7.09%

1M Performance:

+2.32%

6M Performance:

+10.62%

1Y Performance:

-0.31%

1-Day Range:

$94.26

$96.50

1-Week Range:

$90.20

$96.50

52-Week Range:

$73.31

$106.33

Medtronic Plc Stock (MDT) Company Profile

Name

Medtronic Plc

Sector

Healthcare (1052)

Industry

Medical Devices (143)

Phone

01135314381700

Address

BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY

Employee

95,000

Twitter

@Medtronic

Next Earnings Date

2026-11-17

Latest SEC Filings

MDT's Discussions on Twitter

Compare MDT vs ABT, SYK, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MDT Medtronic Plc	94.75	121.20B	36.36B	4.84B	5.43B	3.7261
ABT Abbott Laboratories	104.89	181.50B	46.59B	5.41B	7.38B	3.0938
SYK Stryker Corp	294.66	113.02B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	44.39	64.33B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.60	49.92B	6.30B	1.07B	1.09B	1.8406

Medtronic Plc Stock (MDT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-26	Initiated	Barclays	Equal Weight
Aug-27-26	Reiterated	Needham	Buy
Jul-28-26	Upgrade	UBS	Neutral → Buy
Jun-04-26	Upgrade	BTIG Research	Neutral → Buy
May-21-26	Resumed	Goldman	Neutral
Feb-13-26	Resumed	Barclays	Overweight
Feb-09-26	Upgrade	Needham	Hold → Buy
Feb-03-26	Resumed	Citigroup	Buy
Jan-30-26	Resumed	Wells Fargo	Overweight
Jan-06-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-19-25	Upgrade	Goldman	Sell → Neutral
Jun-30-25	Upgrade	Wolfe Research	Underperform → Peer Perform
Jun-16-25	Initiated	Leerink Partners	Outperform
Mar-04-25	Upgrade	Citigroup	Neutral → Buy
Oct-10-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Aug-21-24	Reiterated	Oppenheimer	Perform
Aug-15-24	Upgrade	UBS	Sell → Neutral
Aug-14-24	Downgrade	Stifel	Buy → Hold
May-30-24	Initiated	Goldman	Sell
Jul-19-23	Initiated	Robert W. Baird	Neutral
Jun-30-23	Initiated	CL King	Buy
May-30-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-24-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-29-23	Downgrade	UBS	Buy → Sell
Jan-09-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-23-22	Downgrade	Citigroup	Buy → Neutral
Nov-23-22	Downgrade	Oppenheimer	Outperform → Perform
Nov-16-22	Downgrade	Deutsche Bank	Buy → Hold
Oct-18-22	Initiated	Barclays	Equal Weight
Oct-13-22	Initiated	Mizuho	Buy
Oct-12-22	Initiated	Jefferies	Hold
Aug-24-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-06-22	Initiated	Wolfe Research	Underperform
Jun-01-22	Downgrade	Atlantic Equities	Overweight → Neutral
May-27-22	Downgrade	Needham	Buy → Hold
Apr-13-22	Downgrade	Truist	Buy → Hold
Mar-02-22	Resumed	BofA Securities	Buy
Jan-10-22	Downgrade	BTIG Research	Buy → Neutral
Jan-07-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-04-22	Downgrade	Piper Sandler	Overweight → Neutral
Dec-17-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-16-21	Downgrade	Wells Fargo	Overweight → Equal Weight
Dec-10-21	Initiated	RBC Capital Mkts	Outperform
Jun-10-21	Resumed	Cowen	Outperform
May-25-21	Initiated	Barclays	Equal Weight
Apr-15-21	Initiated	Atlantic Equities	Overweight
Dec-15-20	Upgrade	Goldman	Sell → Neutral
Dec-15-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-08-20	Upgrade	Bernstein	Mkt Perform → Outperform
Oct-08-20	Upgrade	Stifel	Hold → Buy
Sep-11-20	Initiated	Wolfe Research	Peer Perform
May-14-20	Downgrade	DZ Bank	Buy → Hold
Mar-30-20	Downgrade	Needham	Strong Buy → Buy
Mar-25-20	Upgrade	DZ Bank	Hold → Buy
Mar-05-20	Initiated	Citigroup	Buy
Feb-13-20	Initiated	Goldman	Sell
Jan-08-20	Initiated	SunTrust	Buy
Jan-02-20	Upgrade	Guggenheim	Neutral → Buy
Jun-05-19	Upgrade	Wells Fargo	Market Perform → Outperform
Feb-04-19	Reiterated	Needham	Strong Buy
Jan-03-19	Initiated	Deutsche Bank	Buy
Jan-02-19	Downgrade	Citigroup	Buy → Neutral
Dec-19-18	Upgrade	JP Morgan	Neutral → Overweight
Nov-28-18	Initiated	UBS	Buy
Oct-16-18	Initiated	Barclays	Overweight
Aug-27-18	Reiterated	Argus	Buy

View All

Medtronic Plc Stock (MDT) Latest News

Oct 16, 2026

Is it Apt to Retain Medtronic Stock in Your Portfolio Now? - Zacks Investment Research

Oct 16, 2026

Oct 15, 2026

Medtronic's Stealth AXiS™ and Corsano™ wearable named TIME Best Inventions of 2026 - Pluang

Oct 15, 2026

Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS™ surgical system and Corsano™* multi-parameter wearable - Medtronic

Oct 15, 2026

Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS™ surgical system and Corsano™* multi-parameter wearable - PR Newswire

Oct 15, 2026

A proposed 50,000-share Medtronic (MDT) sale bears Geoffrey Martha’s signature. - Stock Titan

Oct 15, 2026